Eli Lilly Is Already Testing a COVID-19 Antibody Treatment in Humans
A potential new coronavirus treatment could reach hospitals faster than expected thanks to the joint efforts of a pharmaceutical giant and a small, privately held biotech. Eli Lilly (NYSE: LLY), in partnership with AbCellera, has already treated the first patients in a clinical trial for a new COVID-19 treatment candidate, an antibody called LY-CoV555.
The antibody under study was first identified by AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) in a blood sample taken from a patient who had recovered from COVID-19. The big pharma's research and development team has raced LY-CoV555 into the clinical-stage of development just a few months later.
Image source: Getty Images.
Source Fool.com
